Version June 2024
| Joint inflammation and damage: |
| Synovial proliferation and joint effusion |
| Marginal joint erosions |
| Ligamentous laxity and joint deformity |
| Impaired physical function and quality of life |
| Indefinite need for DMARDs |
| Increased risk for development of other diseases |
| Infections |
| Cardiovascular disease |
| Malignancies (lymphoma, lung cancer, skin cancers, among others) |
| Pulmonary disease |
| Life expectancy of RA less than age- and sex-matched control populations, especially in patients with: |
| Polyarticular disease |
| Systemic extraarticular disease |
| Persistent disease activity (high ESR, CRP, and clinical disease activity measures) |
| Rheumatoid factor and circulating immune complex positivity |
| HLA-DRB1 "shared epitope" (especially biallelic) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
